ZOM - Zomedica Pharmaceuticals Corp.

NYSE American - NYSE American Delayed Price. Currency in USD
0.2525
-0.0176 (-6.52%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.2701
Open0.2601
Bid0.0000 x 3000
Ask0.0000 x 900
Day's Range0.2500 - 0.2800
52 Week Range0.2000 - 2.9800
Volume816,998
Avg. Volume343,792
Market Cap29.298M
Beta (3Y Monthly)0.11
PE Ratio (TTM)N/A
EPS (TTM)-0.2820
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire3 days ago

    Zomedica Announces Completion of Initial Development of a Lymphoma Assay for its Canine Cancer Liquid Biopsy Platform

    Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (ZOM.V), a veterinary diagnostic and pharmaceutical company, today announced that it has completed initial development work on a blood-borne lymphoma cancer assay intended for use with its canine cancer liquid biopsy platform. According to the American Veterinary Medical Association, one in four dogs will develop cancer during their lifetime. Lymphomas represent approximately 10-25% of all cancers diagnosed in dogs.

  • GlobeNewswire4 days ago

    Zomedica to Present at Raymond James Life Sciences and MedTech Conference

    ANN ARBOR, Mich., June 12, 2019 -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (TSX-V: ZOM), a veterinary diagnostic and pharmaceutical company, today announced that it.

  • GlobeNewswire6 days ago

    Zomedica Announces $7 Million Second Tranche Closing of Preferred Shares

    ANN ARBOR, Mich., June 10, 2019 -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (TSX-V: ZOM) (“Zomedica” or “Company”), a veterinary diagnostic and pharmaceutical.

  • GlobeNewswire26 days ago

    Zomedica Announces Achievement of Product Development Milestones on its TRUFORMA™ Point-of-Care Diagnostic Platform

    Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (ZOM.V), a veterinary diagnostic and pharmaceutical company, today announced that TRUFORMA™, its point-of-care biosensor platform, recently achieved two important product development milestones. The milestones achieved are beta finalization of the instrument design and the completion of feasibility testing of the TRUFORMA™ platform’s first assays. The standard of care for total T4, fT4, TSH, and cortisol is reference lab immunoassays generally run on expensive laboratory equipment.

  • GlobeNewswirelast month

    Zomedica Announces First Quarter 2019 Financial Results

    Zomedica Pharmaceuticals Corp. (NYSE American:ZOM) (ZOM.V) (“Zomedica” or “Company”), a veterinary diagnostic and pharmaceutical company, today reported consolidated financial results for the first quarter ended March 31, 2019. “During the quarter, we continued to advance the development of our unique product pipeline of novel diagnostics and innovative therapeutics,” said Gerald Solensky Jr., Chairman and CEO of Zomedica. In January 2019, Zomedica announced the achievement of the product development milestone for ZM-017, our canine cancer liquid biopsy diagnostic platform, by Celsee, Inc. Celsee elected to receive its milestone payment in equity resulting in the issuance to Celsee of an aggregate of 657,894 common shares at an ascribed price of $1.52 (C$2.00).

  • GlobeNewswirelast month

    Zomedica Announces Private Placement of Preferred Shares

    Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (ZOM.V) (“Zomedica” or “Company”), a veterinary diagnostic and pharmaceutical company, today announced that it has entered into subscription agreements to sell $12,000,000 of its newly created Series 1 Preferred Shares to an accredited investor under a private placement at a purchase price of $1,000,000 per Series 1 Preferred Share. $5,000,000 of the purchase price was paid on May 9, 2019 and 5 Series 1 Preferred Shares have been issued to the subscriber. The remaining $7,000,000 is expected to be paid on or prior to June 7, 2019, at which time a further 7 Series 1 Preferred Shares will be issuable to the subscriber.

  • GlobeNewswire3 months ago

    Zomedica Pharmaceuticals Corp. Announces Pricing of $3 Million Underwritten Public Offering of Common Shares

    Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (ZOM.V) (“Zomedica” or the “Company”), a veterinary diagnostic and pharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 6,521,740 common shares, at a price to the public of $0.46 per share.  The Company expects to receive gross proceeds of approximately $3 million from the offering.  The offering is expected to close on or about March 28, 2019, subject to customary closing conditions. H.C. Wainwright & Co. is acting as sole book-running manager for the offering.

  • GlobeNewswire3 months ago

    Zomedica Pharmaceuticals Corp. Announces Proposed Public Offering of Common Shares

    Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (ZOM.V) (“Zomedica” or the “Company”), a veterinary diagnostic and pharmaceutical company, today announced it has commenced an underwritten public offering of its common shares. The Company intends to grant the underwriters of the offering a 30-day option to purchase up to an additional 15 percent of the number of common shares sold in connection with the offering. The Company intends to use the net proceeds from the offering for the continued development of its diagnostic platform and therapeutic candidates, including making milestone payments, as they come due, under the Company’s existing license and collaboration agreements, and other general corporate and working capital purposes.

  • GlobeNewswire3 months ago

    Zomedica Initiates ZM-006 Pilot Efficacy Study and Provides Corporate Updates

    Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (ZOM.V), a veterinary diagnostic and pharmaceutical company, initiated enrollment in its pilot efficacy study at the University of Georgia College of Veterinary Medicine to evaluate ZM-006, a transdermal methimazole formulation for the treatment of chronic hyperthyroidism in cats. The ZM-006 pilot efficacy study is being conducted to evaluate Zomedica’s transdermal methimazole formulation and, assuming positive study results, provide data for a future FDA Center for Veterinary Medicine (FDA-CVM) approved pivotal trial.

  • GlobeNewswire4 months ago

    Zomedica Pharmaceuticals Corp. Announces Year End 2018 Financial Results

    Zomedica Pharmaceuticals Corp. (NYSE American:ZOM) (ZOM.V) (“Zomedica” or “Company”), a veterinary diagnostic and pharmaceutical company, today reported consolidated financial results for the year ended December 31, 2018.

  • GlobeNewswire5 months ago

    Zomedica Appoints Dr. Bonnie Bragdon as Vice President of Veterinary Affairs

    Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (ZOM.V), a veterinary diagnostic and pharmaceutical company, today announced the appointment of Bonnie Bragdon, DVM, MS, as Vice President of Veterinary Affairs. In this new company position, she will lead the veterinary medical strategy as it relates to industry trends, strategic partnerships, marketing, education and training to support Zomedica’s commercial product strategy, reporting to Chief Commercial Officer Bruk Herbst. “I am pleased to welcome Dr. Bragdon to the Zomedica Team.

  • GlobeNewswire5 months ago

    Zomedica Announces $4.28 Million Private Placement Closing and Corporate Update

    Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (ZOM.V) (“Zomedica” or “Company”), a veterinary diagnostic and pharmaceutical company, today announced the completion of its previously announced private placement offering, pursuant to which it has issued an aggregate of 2,815,789 common shares at a price of $1.52 (C$2.00) per share, for aggregate gross proceeds of $4,280,000 (approximately C$5,649,600), in the United States to accredited investors only pursuant to the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Rule 506(b) of Regulation D thereunder. Zomedica intends to use the net proceeds of the offering to fund its cash expenditure obligations under the Company’s exclusive development and supply agreement with Qorvo Biotechnologies, LLC (Qorvo), a wholly-owned subsidiary of Qorvo, Inc. (QRVO).

  • GlobeNewswire6 months ago

    Zomedica Provides Update on Pipeline Development and Announces At-The-Market Offering Program

    Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (ZOM.V), a veterinary diagnostic and pharmaceutical company, today provided an update on its pipeline development and announced the entering into of an at-the-market equity offering sales agreement with Cantor Fitzgerald & Co. “2018 was an industrious year in the development and expansion of our diagnostic pipeline alongside the continued development of our therapeutic candidates,” stated Gerald Solensky, Jr., Chairman and Chief Executive Officer at Zomedica. Joint development work initially targets five assay candidates to detect certain thyroid and adrenal disorders in dogs and cats, which currently require reference lab immunoassay testing for reliable diagnostic results.

  • PR Newswire6 months ago

    IncellDx and Zomedica Sign Diagnostic CTC Assay Development Agreement for Canine Cancer

    SAN CARLOS, Calif. , Dec. 19, 2018 /PRNewswire/ -- IncellDx, a leading single cell cancer diagnostics company, today announced it has entered into an assay development agreement with Zomedica (NYSE American: ...

  • Qorvo, Zomedica Tie-Up to Enhance Vet Health with BAW Sensors
    Zacks7 months ago

    Qorvo, Zomedica Tie-Up to Enhance Vet Health with BAW Sensors

    Qorvo's (QRVO) subsidiary, Qorvo Biotechnologies, inked a deal with Zomedica to improve the veterinary health domain with BAW-based filter technology.

  • GlobeNewswire7 months ago

    Zomedica Signs Exclusive Agreement with Qorvo Biotechnologies for Global Veterinary Rights to Diagnostic Point-of-Care Platform

    Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (ZOM.V), a veterinary diagnostic and pharmaceutical company, today announced it has entered into a development and supply agreement with Qorvo Biotechnologies, LLC (Qorvo), a wholly-owned subsidiary of Qorvo, Inc. (QRVO) focused on bringing its piezo-electric Bulk Acoustic Wave (BAW) sensor to the veterinary health sector. Under the terms of this agreement, Zomedica has exclusive, global rights to develop and market Qorvo’s investigational point-of-care diagnostic platform for veterinary use.

  • GlobeNewswire7 months ago

    Zomedica Announces $10 Million Private Offering of Common Shares

    Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (ZOM.V) (“Zomedica” or “Company”), a veterinary diagnostic and pharmaceutical company, today announced it is conducting a private offering of 6,578,947 common shares at a price of U.S.$1.52 (C$2.00) per share, for aggregate gross proceeds of up to U.S.$10,000,000 (approximately C$13,200,000), in the United States to accredited investors only pursuant to the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Rule 506(b) of Regulation D thereunder. Zomedica intends to use the net proceeds of the offering to fund its cash expenditure obligations under the Company’s exclusive development and supply agreement with Qorvo Biotechnologies, LLC (Qorvo), a wholly-owned subsidiary of Qorvo, Inc. (QRVO), announced via press release today.

  • GlobeNewswire7 months ago

    Analysis: Positioning to Benefit within Dominion Energy Midstream Partners, LP, Blue Capital Reinsurance, CRH Medical, Friedman Industries, CM Finance, and Zomedica Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Nov. 26, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GlobeNewswire7 months ago

    Zomedica Pharmaceuticals Corp. Announces Third Quarter 2018 Financial Results

    Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (ZOM.V) (“Zomedica” or “Company”), a veterinary diagnostic and pharmaceutical company, today reported consolidated financial results for the third quarter ended September 30, 2018. Zomedica recorded net loss and comprehensive loss for the three and nine months ended September 30, 2018 of $1,910,278 or $0.02 per share and $8,226,005 or $0.09 per share, compared to a loss of $2,080,682 or $0.02 per share and $5,501,788 or $0.06 per share for the three and nine months ended September 30, 2017. Zomedica, which is in the development stage, recorded no revenues in the three and nine months ended September 30, 2018.

  • GlobeNewswire7 months ago

    Zomedica Pharmaceuticals Corp. to Present at Jefferies 2018 London Healthcare Conference and LD Micro Main Event XI

    ANN ARBOR, Mich., Nov. 12, 2018 -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (TSX-V: ZOM), a veterinary diagnostic and pharmaceutical company, today announced that it.

  • ACCESSWIRE8 months ago

    SeeThruEquity Issues Update on Zomedica Pharmaceuticals Corp.

    NEW YORK, NY / ACCESSWIRE / October 16, 2018 / SeeThruEquity, the leading independent equity research firm focused on smallcap and microcap public companies, today announced it has issued an update note on Zomedica Pharmaceuticals Corp. (NYSE American: ZOM), (ZOM). The report is available here: ZOM Update Note. Based in Ann Arbor, MI, Zomedica Pharmaceuticals Corp. (NYSE American: ZOM, TSXV: ZOM, "Zomedica") is a veterinary diagnostic and pharmaceutical company creating products for companion animals (canine, feline and equine).